Overview
Hypertrichosis lanuginosa congenita (HLC), sometimes referred to as 'congenital generalized hypertrichosis' or historically and colloquially as 'werewolf syndrome,' is an extremely rare genetic condition characterized by excessive growth of fine, soft lanugo hair (the type of hair normally seen on fetuses) covering most of the body. Lanugo hair, which is typically shed before or shortly after birth in unaffected individuals, persists and continues to grow throughout life in people with HLC. The excessive hair growth can cover nearly the entire body surface, including the face, ears, and trunk, though the palms of the hands and soles of the feet are usually spared. Hair length can reach several centimeters and may be lighter or darker depending on the individual's background. The condition primarily affects the integumentary system (skin and hair). Aside from the generalized hypertrichosis, individuals with HLC typically do not have other significant physical abnormalities or intellectual impairment, distinguishing it from other hypertrichosis syndromes that may be associated with gingival hyperplasia or other systemic features. However, some cases have been reported with associated dental anomalies. The excessive hair growth can cause significant psychosocial distress and impact quality of life. There is currently no cure for hypertrichosis lanuginosa congenita. Management is primarily symptomatic and focuses on hair removal techniques, including shaving, waxing, depilatory creams, electrolysis, and laser hair removal, though results vary and regrowth is common. Psychological support and counseling are important components of care, particularly for children and adolescents. Genetic counseling is recommended for affected families. Research into the genetic basis of HLC is ongoing, with some families showing linkage to specific chromosomal regions, but the precise causative gene has not been definitively established in all cases.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Hypertrichosis lanuginosa congenita.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Hypertrichosis lanuginosa congenita at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Hypertrichosis lanuginosa congenita.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Hypertrichosis lanuginosa congenita.
Community
No community posts yet. Be the first to share your experience with Hypertrichosis lanuginosa congenita.
Start the conversation →Latest news about Hypertrichosis lanuginosa congenita
No recent news articles for Hypertrichosis lanuginosa congenita.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Hypertrichosis lanuginosa congenita
What is Hypertrichosis lanuginosa congenita?
Hypertrichosis lanuginosa congenita (HLC), sometimes referred to as 'congenital generalized hypertrichosis' or historically and colloquially as 'werewolf syndrome,' is an extremely rare genetic condition characterized by excessive growth of fine, soft lanugo hair (the type of hair normally seen on fetuses) covering most of the body. Lanugo hair, which is typically shed before or shortly after birth in unaffected individuals, persists and continues to grow throughout life in people with HLC. The excessive hair growth can cover nearly the entire body surface, including the face, ears, and trunk,
How is Hypertrichosis lanuginosa congenita inherited?
Hypertrichosis lanuginosa congenita follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Hypertrichosis lanuginosa congenita typically begin?
Typical onset of Hypertrichosis lanuginosa congenita is neonatal. Age of onset can vary across affected individuals.